science wire

« BACK

Health



Results 201 - 250 of 18754.


Health - 30.09.2019
£420K funding boost for Bristol dementia research
A University of Bristol researcher has been awarded nearly £420,000 by Alzheimer's Research UK to investigate specific changes to blood flow in the brain in Alzheimer's disease.

Pharmacology - Health - 30.09.2019
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi

Health - Life Sciences - 30.09.2019
Young USI researchers on stage at the first Ph.D Biomed Day
Young USI researchers on stage at the first Ph.D Biomed Day
They are 16, determined and ready to dive into the exciting world of research: the first Ph.D students from the new USI Faculty of Biomedical Sciences presented themselves on Friday 20 September at t

Pharmacology - Health - 30.09.2019
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev

Health - Pharmacology - 30.09.2019
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec

Pharmacology - Health - 30.09.2019
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint ,   IRIDIUM is largest study in Phase III PLATINUM clinical development p

Pharmacology - Health - 30.09.2019
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu

Pharmacology - Health - 29.09.2019

Pharmacology - Health - 28.09.2019
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years Roche will present new data at the Europea

Pharmacology - Health - 27.09.2019
Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil

Health - Life Sciences - 27.09.2019
Moving beyond hype: Could one-two treatment restore damaged heart muscle?
Heart attacks can cause immediate death. But in survivors, the blockage of blood flow can kill so many heart muscle cells that heart failure can follow months or years afterwards.

Pharmacology - Health - 27.09.2019
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by 45% compared with Tecentriq monotherapy Data from the Phase Ib cancer immunotherapy combination study will be presented at the European So

Health - Life Sciences - 27.09.2019
UW-Madison, local startup testing a one-two punch against hard-to-heal wounds
The silver-containing MicroLyte bandage is thinner than a human hair and able to be absorbed into the wound.

Health - 27.09.2019

Health - Pharmacology - 26.09.2019
UCLA to lead $25 million study of opioids in rural America
Scientists from the UCLA Integrated Substance Abuse Programs will lead a $25 million study on in rural America.

Social Sciences - Health - 26.09.2019
Stanford announces newest cohort of DARE fellows
Twenty-four Stanford doctoral students have been named to the newest cohort of the Diversifying Academia, Recruiting Excellence (DARE) Doctoral Fellowship Program.

Health - Veterinary Science - 26.09.2019
Standing CT for horses, developed at UW-Madison, fills longstanding need in veterinary medicine
A horse's hind legs are scanned in a new standing helical computed tomography (CT) scanner developed at the University of Wisconsin-Madison and now available for patients of the School of Veterinary Medicine's Morrie Waud Large Animal Hospital.

Health - Pharmacology - 26.09.2019
Spotlight on... Dr Jane Kinghorn
This week Jane, Director of the Translational Research Office (TRO), talks about developing solutions to unmet medical needs, and new support for Early Career Researchers.

Business / Economics - Health - 24.09.2019

Pharmacology - Health - 23.09.2019
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici

Event - Health - 20.09.2019
Veterinary surgeons awarded ‘impact award' for changing antimicrobial use in veterinary practice
Veterinary surgeons awarded ‘impact award’ for changing antimicrobial use in veterinary practice
Veterinary researchers from the universities of Bristol and Surrey have been awarded a prestigious award by the Veterinary Record, the official journal of the British Veterinary Association (BVA), for their contribution to changing antimicrobial use in veterinary practice.

Health - Life Sciences - 20.09.2019

Life Sciences - Health - 20.09.2019
New world-leading facility for UCL Neuroscience gains planning approval
UCL is delighted to announce that conditional planning permission* has been granted for a new £281.6m state-of-the-art facility, which will be home to UCL Neuroscience.

Health - Pharmacology - 20.09.2019
FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti

Life Sciences - Health - 19.09.2019
How to construct a protein factory
How to construct a protein factory
The complexity of molecular structures in the cell is amazing. Having achieved great success in elucidating these structures in recent years, biologists are now taking on the next challenge: to find out more about how they are constructed. A joint research project between two groups from the University of Bern and ETH Zurich now provides insight into a very unusual construction process in the unicellular parasite Trypanosoma brucei.

Pharmacology - Health - 19.09.2019
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1

Health - Philosophy - 18.09.2019
William Meadow, pioneer in neonatal intensive care and medical ethics, 1948-2019
Prof. William L. Meadow, a leading authority on the care of infants born prematurely or with significant health concerns, died Sept.

Health - Life Sciences - 18.09.2019
Brain implant restores visual perception to the blind
Seven years ago, Jason Esterhuizen was in a horrific car crash that destroyed his eyes, plunging him into total darkness.

Pharmacology - Health - 18.09.2019
FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Full results from the NOBILITY study will be presented at a medical meeting later this year Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for adults with lupus nephritis.

Health - Computer Science / Telecom - 17.09.2019
Prestigious grant to use Artificial Intelligence for improved glucose control
Prestigious grant to use Artificial Intelligence for improved glucose control
The ARTORG Center for Biomedical Engineering Research of the University of Bern is the recipient of a grant from JDRF, the leading global funder for type 1 diabetes research.

Pharmacology - Health - 17.09.2019
Novartis Cosentyx positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).

Life Sciences - Health - 16.09.2019
In human cells and mice, a cure for the common cold, Stanford-UCSF study reports
Disabling a single, apparently noncritical protein in cells may foil replication of the viruses that cause half of all common colds, polio and other diseases, according to researchers at Stanford and UCSF. Temporarily disabling a single protein inside our cells might be able to protect us from the common cold and other viral diseases, according to a study led by researchers at Stanford University and University of California-San Francisco.

Computer Science / Telecom - Health - 16.09.2019
AI to enhance manufacturing, energy, and healthcare thanks to £6.5m EPSRC grant
The grant will help scientists, engineers, and clinicians train algorithms to solve energy, manufacturing, and healthcare problems.

Environment - Health - 16.09.2019
UCL launches new campaign to celebrate its disruptive discoveries
UCL is today launching the public phase of its major new campaign #MadeAtUCL to celebrate over 100 disruptive discoveries pioneered by some of the university's leading researchers.

Health - Veterinary Science - 16.09.2019

Pharmacology - Health - 13.09.2019
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos

This site uses cookies and analysis tools to improve the usability of the site. More information. |